Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;8(1):45-55.
doi: 10.2217/imt.15.103. Epub 2015 Dec 7.

Novel targets for natural killer/T-cell lymphoma immunotherapy

Takumi Kumai  1 , Hiroya Kobayashi  2 , Yasuaki Harabuchi  1   2
Affiliations
Review

Novel targets for natural killer/T-cell lymphoma immunotherapy

Takumi Kumai et al. Immunotherapy. 2016.

Abstract

Extranodal natural killer/T-cell lymphoma, nasal type (NKTL) is a rare but highly aggressive Epstein-Barr virus-related malignancy, which mainly occurs in nasopharyngeal and nasal/paranasal areas. In addition to its high prevalence in Asian, Central American and South American populations, its incidence rate has been gradually increasing in Western countries. The current mainstay of treatment is a combination of multiple chemotherapies and irradiation. Although chemoradiotherapy can cure NKTL, it often causes severe and fatal adverse events. Because a growing body of evidence suggests that immunotherapy is effective against hematological malignancies, this treatment could provide an alternative to chemoradiotherapy for treatment of NKTL. In this review, we focus on how recent findings could be used to develop efficient immunotherapies against NKTL.

Keywords: CCR4; Epstein–Barr virus; c-Met; chemokine; immunotherapy; mutation; natural killer/T-cell lymphoma; peptide vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources